He holds a postgraduate degree in Pharmaceutics from Rajiv Gandhi University of Health Sciences, Karnataka. With over 20 years of experience in Pharmaceutical Research and Development, he has become an expert in designing and developing differentiated dosage forms, as well as mapping regulatory pathways for 505(b)2 or hybrid products.
His extensive experience includes developing innovative products that involve changes in the route of administration, indications and salts, as well as strategies to avoid co-medication in cancer therapy.
He is also highly knowledgeable in biostatistics and has made significant contributions to the design of pre-clinical and clinical studies. For over two decades, he has led multiple portfolios for global development, taking primary responsibility for the design, planning and execution of various projects. His work spans the development of dermatology products, oncology injectables oral medications and supportive oncology therapies.
His rich experience in meeting global regulatory requirements has been instrumental in the successful development and approval of numerous pharmaceutical products.
Before founding WohlStand Pharma, His career includes significant roles at esteemed pharmaceutical companies such as Sun Pharma, Panacea Biotec, Abbott Healthcare and Shilpa Medicare. In these positions, he has consistently demonstrated his ability to drive innovation and ensure compliance with regulatory standards, making him a valuable asset to any organization he collaborates with.